Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
PR Newswire —
Issued on behalf of Helus Pharma VANCOUVER, BC, Feb. 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary — Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The...